←
N1 Collaborative31 posts
N1 Collaborative avatar

N1 Collaborative

@N1Collaborative

Working together to bring individualized genetic medicines safely and rapidly to patients worldwide

◷ Joined January 2023▧ 15 Photos and videos
N1 Collaborative avatar
N1 Collaborative@N1Collaborative·14 Sep 2023

Individualized medicine provides new opportunities for targeted therapies for rare disease patients, but not all individuals affected by rare disease are eligible for tailored N=1 approaches.

Post attachment
N1 Collaborative avatar
N1 Collaborative@N1Collaborative·7 Sep 2023

Join us for a case study on Monday, September 11, at 12:30 pm US EDT to hear about ASO treatment for SCN2A-encephalopathy, allele-specific vs non-specific, with Heather Olson and Elizabeth Berry-Kravis. Register here: bit.ly/487WDhC

Post attachment
N1 Collaborative avatar
N1 Collaborative@N1Collaborative·24 Aug 2023

For N-of-1/few treatments in rare genetic disease, while antisense oligos may be the initial therapeutic platform of choice, CRISPR holds huge promise for the future.

N1 Collaborative avatar
N1 Collaborative@N1Collaborative·27 Jul 2023

Join us for a case study on Monday, July 31, at 12:30 pm US EDT to hear about a novel antisense oligonucleotide for CMT2S, a rare subtype of Charcot-Marie-Tooth Disease, with Sandra Smieszek of Vanda Pharmaceuticals.

Post attachment
N1 Collaborative avatar
N1 Collaborative@N1Collaborative·14 Jul 2023

Join Andrew Lo, @MIT Sloan Professor of Finance, this Monday for a dynamic seminar hosted by the @N1Collaborative. We will discuss the portfolio model in rare disease therapeutics, the role of philanthropy, and reimbursement considerations in the individualized medicine context.

N1 Collaborative avatar
N1 Collaborative@N1Collaborative·6 Jul 2023

What if coding personalized ASO therapies only required the press of a button? Join us Monday, July 10, at 12:30pm US EDT, and Vanessa Almendro of @DanaherCorp to discuss the paradigm shift needed to make therapeutic interventions for rare genetic diseases accessible to patients.

N1 Collaborative avatar
N1 Collaborative@N1Collaborative·2 Jun 2023

Join Emil Kakkis, CEO of Ultragenyx & Richard Finkel, MD, Director, Center for Experimental Neurotherapeutics, St. Jude Children's Hospital, at the @N1Collaborative seminar Monday, June 5 at 12:30 PM EDT to discuss how to think about outcome measures for individualized medicines.

Post attachment
N1 Collaborative avatar
N1 Collaborative@N1Collaborative·18 May 2023

Join us on Monday, May 22, at 12:30pm US EDT, for the next @N1Collaborative seminar to discuss this critical topic with Dr. Matthis Synofzik and Dr. Rebecca Schüle from University of Tuebingen Join live: https://t.co/Pmidn3hR9M